Starpharma Holdings Ltd Asset Resilience Ratio
Starpharma Holdings Ltd asset resilience ratio. Starpharma Holdings Ltd (SPL) has an Asset Resilience Ratio of 69.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SPL defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Starpharma Holdings Ltd (2016–2025)
Asset resilience ratio of Starpharma Holdings Ltd from 2016 to 2025. This chart shows how Starpharma Holdings Ltd's Asset Resilience Ratio has changed over time. Read Starpharma Holdings Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Starpharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Starpharma Holdings Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$18.25 Million | 69.74% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$18.25 Million | 69.74% |
Asset Resilience Insights
- Very High Liquidity: Starpharma Holdings Ltd maintains exceptional liquid asset reserves at 69.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Starpharma Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Starpharma Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Starpharma Holdings Ltd Asset Resilience Ratio by Year (2016–2025)
Starpharma Holdings Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Starpharma Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 59.40% | AU$15.10 Million ≈ $10.68 Million |
AU$25.42 Million ≈ $17.99 Million |
-2.61pp |
| 2024-06-30 | 62.01% | AU$22.83 Million ≈ $16.15 Million |
AU$36.81 Million ≈ $26.05 Million |
-2.34pp |
| 2023-06-30 | 64.35% | AU$33.52 Million ≈ $23.72 Million |
AU$52.09 Million ≈ $36.85 Million |
-4.85pp |
| 2022-06-30 | 69.20% | AU$45.79 Million ≈ $32.40 Million |
AU$66.17 Million ≈ $46.82 Million |
-9.04pp |
| 2021-06-30 | 78.24% | AU$57.30 Million ≈ $40.54 Million |
AU$73.24 Million ≈ $51.82 Million |
+11.74pp |
| 2020-06-30 | 66.49% | AU$25.98 Million ≈ $18.39 Million |
AU$39.08 Million ≈ $27.65 Million |
-11.91pp |
| 2019-06-30 | 78.40% | AU$38.31 Million ≈ $27.10 Million |
AU$48.86 Million ≈ $34.57 Million |
-3.58pp |
| 2018-06-30 | 81.98% | AU$47.97 Million ≈ $33.94 Million |
AU$58.51 Million ≈ $41.40 Million |
-4.88pp |
| 2017-06-30 | 86.85% | AU$57.84 Million ≈ $40.92 Million |
AU$66.59 Million ≈ $47.12 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$59.04 Million ≈ $41.77 Million |
-- |
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRA… Read more